WuXi STA plant gets FDA nod for 2 APIs, passing its first inspection

WuXi has passed its first FDA inspection at its API plant in Changzhou, China. (WuXi)

The solid-dose API operation of China’s WuXi had its first visit by FDA inspectors at a new plant in Changzhou, China, and the company says it aced it.

The facility won FDA approval for two APIs during a preapproval inspection that was concluded with no observations, WuXi’s SynTheAll Pharmaceutical (STA) said Monday.  

“The Changzhou facility passing its first FDA inspection, with no observations, even with no written or verbal recommendations, is yet further proof of our commitment to the highest possible quality standards,” WuXi STA CEO Minzhang Chen said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The CDMO has previously passed FDA inspections at its production sites in Shanghai, Jinshan and Shanghai, Waigaoqiao.

RELATED: A year in, WuXi's STA bulks up its API R&D engineering at China site

The site in Changzhou opened in 2016 and currently has three plants and more than 1,000 employees, including 200 scientists, the company said. It is being built in stages but when all is said and done, it will include more than 500 scientists and 1,500 cubic meters of reactor volume. It currently has more than five dozen APIs and/or intermediates under development and one NCE in commercial production.

RELATED: China's WuXi Biologics to build biologics plant in Ireland that will employ 400

STA is not part of WuXi's biologics operations, which the company also is expanding. Last month, WuXi Biologics announced plans to invest €325 million ($392 million) to build a biologics facility in Dundalk, Ireland, and create a campus of 26 hectares (2.8 million square feet). The project is its first outside of China where it currently boasts the largest biologics plant build on single-use bioreactor technology.

Suggested Articles

Glenmark hopes to raise cash from selling drugs outside of its focus therapeutic areas and from finding new investors for its API and innovation spinoffs.

Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.